ERBB2 and non-small cell lung carcinoma: With growing evidence that anti-HER2 targeted therapy provides clinical efficacies in HER2-altered NSCLC, a comprehensive understanding of the clinical and molecular characteristics of HER2-altered NSCLC tumors is urgently needed.